Upgrade to SI Premium - Free Trial

Eli Lilly & Co. (LLY) Reports Interim Results for MONARCH 3 Study Highlighting Benefit of Verzenio (Abemaciclib) Plus NSAI in Advanced Breast Cancer

October 6, 2017 1:02 PM
Eli Lilly and Company (NYSE: LLY) today announced that interim results from the double-blind, placebo-controlled Phase 3 MONARCH 3 study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Next Articles